Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer

Anti-Cancer Drugs

Volumn 24, Issue 3, 2013, Pages 237-250

  Jia, Jingquan ^a   Starodub, Alex ^b   Cushman, Ian ^a   Liu, Yingmiao ^a   Marshall, Deborah J ^c   Hurwitz, Herbert I ^a   Nixon, Andrew B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c Jassen Pharmaceuticals RandD   (United States)

Author keywords

colorectal cancer; focal adhesion kinase; integrins; paxillin; Src

Indexed keywords

CD51 ANTIGEN; DASATINIB; INTETUMUMAB; PAXILLIN; PROTEIN TYROSINE KINASE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVATION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FOCAL ADHESION KINASE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAV; PAXILLIN; PHOSPHORYLATION; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES;

EID: 84873412467     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835d29fd     Document Type: Article

References (47)

1. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001; 305:285-298
2. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275:21785-21788
3. Stupack DG, Cheresh DA. Get a ligand, get a life: Integrins, signaling and cell survival. J Cell Sci 2002; 115:3729-3738
4. Schuppan D, Ocker M. Integrin-mediated control of cell growth. Hepatology 2003; 38:289-291
5. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2:91-100
6. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002; 110:673-687
7. GuoW, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5:816-826
8. Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, et al. Alpha-V integrins as therapeutic targets in oncology. Cancer Invest 2007; 25:632-646
9. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64:207-238
10. Jin H, Varner J. Integrins: Roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-565
11. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Differential clinical significance of alpha(v)beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer 2000; 89:153-159
12. Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 2000; 7:19-26
13. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, et al. Expression of alphav integrin family in gastric carcinomas: Increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract 2003; 199:57-64
14. Sato T, Konishi K, Maeda K, Yabushita K, Miwa A. Integrin alpha v, c-ErbB2 and DNA ploidy in lung metastases from colorectal cancer. Hepatogastroenterology 2003; 50:27-30
15. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA. Cadherins and integrins in renal cell carcinoma: An immunohistochemical study. Tumori 2001; 87:173-178
16. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002; 4:191-194
17. Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, et al. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 2001; 7:4073-4079
18. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004; 110:326-335
19. Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, et al. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 2008; 25:139-148
20. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, et al. Phase I evaluation of a fully human anti-Alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007; 13:2128-2135
21. Chu FM, Picus J, Fracasso PM, Dreicer R, Lang Z, Foster B. A phase 1, multicenter, open-Label study of the safety of two dose levels of a human monoclonal antibody to human alpha(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrateresistant metastatic prostate cancer. Invest New Drugs 2011; 29:674-679
22. O'Day SJ, Pavlick AC, Albertini MR, Hamid O, Schalch H, Lang Z, et al. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drugs 2012; 30:1074-1081
23. O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, et al. A randomised, phase II study of intetumumab, an anti-Alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011; 105:346-352
24. Martin GS. The road to Src. Oncogene 2004; 23:7910-7917
25. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609
26. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19:5636-5642
27. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-Src in progressive stages of human colorectal cancer. J Clin Invest 1993; 91:53-60
28. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658-6661
29. Olivieri A, Manzione L. Dasatinib: A new step in molecular target therapy. Ann Oncol 2007; 18 (SUPPL6):vi42-Vi46
30. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004; 23:7928-7946
31. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18:516-523
32. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4:722-731
33. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, et al. Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4:2625-2634
34. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980; 288: 551-556
35. Desgrosellier JS, Cheresh DA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9-22
36. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: The first antiangiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010; 10:753-768
37. Shannon KE, Keene JL, Settle SL, Duffin TD, Nickols MA, Westlin M, et al. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis 2004; 21:129-138
38. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007; 67:5821-5830
39. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther 2008; 7: 1569-1578
40. Lee EC, Lotz MM, Steele GD Jr, Mercurio AM. The integrin alpha 6 beta 4 is a laminin receptor. J Cell Biol 1992; 117:671-678
41. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 2008; 68:7323-7331
42. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorageindependence and tumor progression. Nat Med 2009; 15: 1163-1169
43. Schwartz MA, Ginsberg MH. Networks and crosstalk: Integrin signalling spreads. Nat Cell Biol 2002; 4:E65-E68
44. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032
45. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: Mediators and therapeutic targets. Endothelium 2006; 13:113-135
46. Bellis SL, Perrotta JA, Curtis MS, Turner CE. Adhesion of fibroblasts to fibronectin stimulates both serine and tyrosine phosphorylation of paxillin. Biochem J 1997; 325 (Pt 2):375-381
47. Turner CE. Paxillin interactions. J Cell Sci 2000; 113 (Pt 23): 4139-4140